JP2021527095A5 - - Google Patents
Info
- Publication number
- JP2021527095A5 JP2021527095A5 JP2020569143A JP2020569143A JP2021527095A5 JP 2021527095 A5 JP2021527095 A5 JP 2021527095A5 JP 2020569143 A JP2020569143 A JP 2020569143A JP 2020569143 A JP2020569143 A JP 2020569143A JP 2021527095 A5 JP2021527095 A5 JP 2021527095A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- dihydro
- purine
- methylquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685325P | 2018-06-15 | 2018-06-15 | |
| US62/685,325 | 2018-06-15 | ||
| PCT/EP2019/065686 WO2019238929A1 (en) | 2018-06-15 | 2019-06-14 | Purinone compounds and their use in treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527095A JP2021527095A (ja) | 2021-10-11 |
| JP2021527095A5 true JP2021527095A5 (cg-RX-API-DMAC7.html) | 2022-06-23 |
| JP7472044B2 JP7472044B2 (ja) | 2024-04-22 |
Family
ID=67107385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569143A Active JP7472044B2 (ja) | 2018-06-15 | 2019-06-14 | プリノン化合物及び癌の治療におけるそれらの使用 |
Country Status (29)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI899080B (zh) | 2019-05-27 | 2025-10-01 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna依賴性蛋白激酶抑制劑 |
| WO2021104277A1 (zh) * | 2019-11-25 | 2021-06-03 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的嘧啶并咪唑类化合物 |
| KR102786205B1 (ko) * | 2019-12-31 | 2025-03-31 | 청두 바이위 파머수티컬 씨오., 엘티디 | 퓨린 유도체 및 의학에서의 그의 용도 |
| WO2021136461A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| CN113121538B (zh) * | 2019-12-31 | 2023-04-21 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| WO2021204111A1 (zh) * | 2020-04-10 | 2021-10-14 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物 |
| BR112022020962A2 (pt) * | 2020-04-17 | 2022-12-06 | Chengdu Baiyu Pharmaceutical Co Ltd | Derivados de imidazolidinona e uso médico dos mesmos |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2022017368A1 (zh) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| CA3192868A1 (en) * | 2020-09-24 | 2022-03-31 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| CN114656486B (zh) * | 2020-12-22 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
| TW202229281A (zh) * | 2020-12-24 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |
| CN116917288B (zh) * | 2021-03-22 | 2026-04-14 | 成都赜灵生物医药科技股份有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| US20240300977A1 (en) * | 2021-04-17 | 2024-09-12 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
| CN117377676B (zh) * | 2021-06-29 | 2026-04-07 | 康百达(四川)生物医药科技有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| WO2023036156A1 (zh) * | 2021-09-07 | 2023-03-16 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| WO2025199376A1 (en) * | 2024-03-22 | 2025-09-25 | Padarn Therapeutics, Inc. | Cdk2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2212326A1 (en) * | 2007-08-23 | 2010-08-04 | AstraZeneca AB | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| WO2010118207A1 (en) * | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| JP5759471B2 (ja) * | 2009-10-29 | 2015-08-05 | ヴェクチュラ リミテッド | Jak3キナーゼ阻害剤としての窒素含有ヘテロアリール誘導体 |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| MX2013010439A (es) * | 2011-03-11 | 2014-07-09 | Gilead Calistoga Llc | Tratamientos combinados para neoplasias hematologicas. |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| DK3558997T3 (da) * | 2016-12-20 | 2021-04-19 | Astrazeneca Ab | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer |
-
2019
- 2019-06-06 TW TW108119642A patent/TWI820146B/zh active
- 2019-06-14 SG SG11202012035WA patent/SG11202012035WA/en unknown
- 2019-06-14 CR CR20200620A patent/CR20200620A/es unknown
- 2019-06-14 ES ES19734289T patent/ES2931448T3/es active Active
- 2019-06-14 MA MA052886A patent/MA52886A/fr unknown
- 2019-06-14 CN CN201980038412.5A patent/CN112236431B/zh active Active
- 2019-06-14 UA UAA202100011A patent/UA126837C2/uk unknown
- 2019-06-14 KR KR1020207037917A patent/KR102793666B1/ko active Active
- 2019-06-14 CA CA3102195A patent/CA3102195A1/en active Pending
- 2019-06-14 MX MX2020013570A patent/MX2020013570A/es unknown
- 2019-06-14 IL IL279370A patent/IL279370B2/en unknown
- 2019-06-14 EA EA202190006A patent/EA202190006A1/ru unknown
- 2019-06-14 AR ARP190101659A patent/AR114971A1/es unknown
- 2019-06-14 US US16/973,862 patent/US11884671B2/en active Active
- 2019-06-14 UY UY0001038263A patent/UY38263A/es active IP Right Grant
- 2019-06-14 AU AU2019287295A patent/AU2019287295B2/en active Active
- 2019-06-14 WO PCT/EP2019/065686 patent/WO2019238929A1/en not_active Ceased
- 2019-06-14 EP EP19734289.2A patent/EP3807278B1/en active Active
- 2019-06-14 JP JP2020569143A patent/JP7472044B2/ja active Active
- 2019-06-14 PE PE2020002005A patent/PE20210003A1/es unknown
- 2019-06-14 BR BR112020025127-5A patent/BR112020025127A2/pt unknown
-
2020
- 2020-12-02 CL CL2020003131A patent/CL2020003131A1/es unknown
- 2020-12-07 JO JOJO/P/2020/0315A patent/JOP20200315B1/ar active
- 2020-12-09 DO DO2020000241A patent/DOP2020000241A/es unknown
- 2020-12-10 NI NI202000099A patent/NI202000099A/es unknown
- 2020-12-11 EC ECSENADI202080276A patent/ECSP20080276A/es unknown
- 2020-12-12 PH PH12020552148A patent/PH12020552148A1/en unknown
- 2020-12-15 CO CONC2020/0015758A patent/CO2020015758A2/es unknown
-
2021
- 2021-01-12 ZA ZA2021/00195A patent/ZA202100195B/en unknown
-
2023
- 2023-12-14 US US18/540,129 patent/US20240150355A1/en not_active Abandoned
-
2025
- 2025-02-28 UY UY0001041072A patent/UY41072A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12291539B2 (en) | KRAS G12C inhibitors | |
| JP6893501B2 (ja) | スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン | |
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP7592689B2 (ja) | Stingアゴニストとしての大環状化合物並びにその方法及び使用 | |
| US10745382B2 (en) | Compounds useful as immunomodulators | |
| WO2024138206A1 (en) | Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof | |
| ES2820827T3 (es) | Formas sólidas de un compuesto modulador de quinasas | |
| JP4739761B2 (ja) | キナーゼ抑制物質としてのピロロ−ピラゾール置換誘導体 | |
| ES2826950T3 (es) | Métodos para tratar cáncer y afecciones no neoplásicas | |
| JP5878171B2 (ja) | 抗ウイルス剤としてのピラゾロ[1,5−a]ピリミジン | |
| ES3062441T3 (en) | Antiviral compounds | |
| JP6756435B2 (ja) | Trail誘導のためのファーマコフォア | |
| WO2024229444A2 (en) | Mutant kras inhibitors and uses thereof | |
| ES2821400T3 (es) | Compuestos de 6-heterociclil-4-morfolin-4-ilpiridin-2-ona útiles para el tratamiento del cáncer y la diabetes | |
| JP2018527398A (ja) | ヘテロ環式化合物およびそれらの使用 | |
| JP2017510595A5 (cg-RX-API-DMAC7.html) | ||
| EA020703B1 (ru) | Пиразолохиназолины | |
| CN111670183A (zh) | 作为cdk8/19抑制剂的新型杂环化合物 | |
| JP2018526391A5 (cg-RX-API-DMAC7.html) | ||
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2025516543A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2005097803A1 (ja) | 新規水溶性プロドラッグ | |
| EP3590516B1 (en) | Antitumor-effect enhancer using pyrazolo[3,4-d]pyrimidine compound | |
| AU2018320419A1 (en) | Morpholinylpyridone compounds |